Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

A former Pfizer Inc. scientist denied an allegation made by House Republicans that he conspired to delay the release of Covid ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

The Delaware Supreme Court ruled in favor of companies including GSK (NYSE:GSK), Pfizer (NYSE:PFE), and Boehringer Ingelheim on Thursday, rejecting the legitimacy of expert testimony that linked tens ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

Korea has developed the world's first recombinant protein-based anthrax vaccine, a major step toward self-sufficiency that ...

BioNTech has announced the acquisition of fellow German biotech CureVac in an all-stock transaction valued at approximately ...

SEONGNAM, South Korea, May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it ...

However, due to the ongoing patent dispute with Pfizer, the company has been prohibited from manufacturing and selling the vaccine in Korea until 2027, when the related patents set to expire.

The patent battle over RSV vaccines highlights intensifying competition in the global vaccine market. Despite dropping this particular case, legal tensions remain between GSK and Pfizer.

Freshfields has won a Düsseldorf regional court patent dispute on behalf of client Moderna against German COVID-19 vaccine inventors BioNTech and Pfizer. BioNTech, represented by Taylor Wessing ...